Buy Like Buffett
Watchlist

Flagship explainer

What drives Verrica Pharmaceuticals Inc.’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity−240%Tax burden100%net income ÷ pretax incomeInterest burden147%pretax ÷ operating incomeOperating margin−34%operating income ÷ revenueAsset turnover0.70×revenue ÷ average assetsEquity multiplier6.80×average assets ÷ average equityAs of 2025-12-31 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
−$17.9MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001660334-26-000008 · filed Mar 11, 2026
Income before tax−$17.9MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001660334-26-000008 · filed Mar 11, 2026
Operating income−$12.2MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001660334-26-000008 · filed Mar 11, 2026
$35.6MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001660334-26-000008 · filed Mar 11, 2026
Ending assets$47.1MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001660334-26-000008 · filed Mar 11, 2026
Beginning assets$54.1MFY2024
  • 10-K · FY 2024Filing detailsAccession 0000950170-25-037172 · filed Mar 11, 2025
  • 10-K · FY 2024Filing detailsAccession 0001660334-26-000008 · filed Mar 11, 2026
$24.7MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001660334-26-000008 · filed Mar 11, 2026
−$9.9MFY2024
  • 10-K · FY 2024Filing detailsAccession 0000950170-25-037172 · filed Mar 11, 2025
  • 10-K · FY 2024Filing detailsAccession 0001660334-26-000008 · filed Mar 11, 2026
Source: · event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set
Embed this chart

View the full Verrica Pharmaceuticals Inc. analysis at Buy Like Buffett